Dyserythropoiesis evaluated by RED score and hepcidin/ferritin levels predicts response to erythropoietin in lower risk myelodysplastic syndromes.

Dyserythropoiesis evaluated by RED score and hepcidin/ferritin levels predicts response to erythropoietin in lower risk myelodysplastic syndromes. Haematologica. 2018 Oct 04;: Authors: Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M Abstract Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in lower risk myelodysplastic syndrome patients. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythropoiesis including flow cytometry RED score, serum GDF-15, and hepcidin levels. Inclusion criteria were: Erythropoiesis stimulating agents naive, IPSS low or intermediate-1 MDS with Hemoglobin level< 10g/dl, red blood cell transfusion-dependent or not. Patients received epoetin zeta 40 000 IU/week and erythroid response (IWG 2006 criteria) was assessed at week 12. Serum EPO level, iron parameters and hepcidin, flow cytometry Ogata and RED score, GDF-15, and molecular analysis by next-generation sequencing were determined at baseline. 70 patients were included. Median age was 78 years. There were 22 ...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research